Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

First human test of potential enterovirus drug begins

NCT ID NCT06444048

Summary

This is an early safety study of a new drug called EV68-228-N, which is being developed to treat enterovirus infections. The study enrolled 36 healthy adult volunteers to test three different doses of the drug, given as a single infusion into a vein. The main goals are to see if the drug is safe and to measure how long it stays in the body.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ENTEROVIRUS INFECTION are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Locations

  • University of Maryland, School of Medicine, Center for Vaccine Development and Global Health

    Baltimore, Maryland, 21201-1509, United States

  • Vanderbilt University Medical Center

    Nashville, Tennessee, 37232-0011, United States

Conditions

Explore the condition pages connected to this study.